Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $14.34B | $14.2B | +0.99% |
Operating Income | $3.58B | $3.99B | -10.34% |
Net Income | $4.5B | $4.41B | +2.09% |
EPS (Basic) | $43.07 | $40.90 | +5.31% |
EPS (Diluted) | $41.48 | $38.34 | +8.19% |
R&D Expense | $5.85B | $5.13B | +13.99% |
SG&A Expense | $2.7B | $2.95B | -8.61% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $40.56B | $37.76B | +7.41% |
Current Assets | $18.02B | $18.66B | -3.42% |
Total Liabilities | $9.3B | $8.41B | +10.66% |
Current Liabilities | $4.37B | $3.94B | +10.75% |
Stockholders' Equity | $31.26B | $29.35B | +6.48% |
Cash & Equivalents | $3.12B | $2.49B | +25.32% |
Long-Term Debt | $1.99B | $1.98B | +0.08% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $4.98B | $4.42B | +12.63% |
Investing Cash Flow | $-629.1M | $-2.47B | +74.51% |
Financing Cash Flow | $-3.72B | $-2.2B | -68.84% |
Dividends Paid | $370.3M | $0 | — |
Share Buybacks | $3.44B | $2.6B | +32.09% |
D&A | $543.7M | $482.9M | +12.59% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Margin | 24.9% | 28.1% | -3.15% |
Net Margin | 31.4% | — | — |
ROE | 14.4% | — | — |
ROA | 11.1% | — | — |
Current Ratio | $4.126 | — | — |
Debt to Equity | $0.298 | — | — |
REGN's 2025 financial performance shows modest revenue growth and improved net income despite increased R&D expenses and declining operating income.
The company achieved a 1.0% increase in revenue, driven by strong product sales and strategic partnerships.
Source: Source: 10-K Item 7, p.45
R&D expenses rose by 14.0%, reflecting the company's commitment to innovation and pipeline expansion.
Source: Source: 10-K Item 7, p.46
SG&A expenses decreased by 8.6%, indicating effective cost management strategies.
Source: Source: 10-K Item 7, p.47
The significant rise in R&D expenses could pressure margins if new products do not achieve expected commercial success.
Source: Source: 10-K Item 1A, p.12
Unlock 2 more detailed risk analysis
Upgrade to unlockOther companies in Biotechnology